IP
The startup develops a drug-polymer delivery system for ocular treatment, allowing patients to self-administer a mixture that releases therapeutic agents directly into the eye. This technology addresses the challenge of effectively managing chronic eye diseases by providing a controlled release mechanism that enhances treatment adherence and efficacy.
Updated 18 months ago
Funding
$200K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PV
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a drug-polymer delivery system for ocular treatment, allowing patients to self-administer a mixture that releases therapeutic agents directly into the eye. This technology addresses the challenge of effectively managing chronic eye diseases by providing a controlled release mechanism that enhances treatment adherence and efficacy.